"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 4 | 5 |
| 1999 | 1 | 2 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 1 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 4 | 5 |
| 2006 | 2 | 1 | 3 |
| 2007 | 7 | 2 | 9 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 4 | 5 | 9 |
| 2012 | 2 | 6 | 8 |
| 2013 | 1 | 3 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 9 | 11 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 5 | 7 |
| 2019 | 0 | 3 | 3 |
| 2020 | 6 | 5 | 11 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy. Mol Imaging. 2024 Jan-Dec; 23:15353508241280015.
-
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2025 01; 177:108834.
-
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Radiol Oncol. 2024 Sep 01; 58(3):348-356.
-
In Vivo Mapping of Myocardial Injury Outside the Infarct Zone: Tissue at an Intermediate Pathological State. J Am Heart Assoc. 2024 May 07; 13(9):e032577.
-
Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
-
Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 May; 35(5):712-721.e3.
-
A simplified protocol for the automated production of 2-[18 F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine ([18 F]nifene) on an IBA Synthera® module. J Labelled Comp Radiopharm. 2024 Jan; 67(1):31-36.
-
Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma. Clin Lung Cancer. 2023 05; 24(3):244-251.
-
Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients. Cancer Control. 2023 Jan-Dec; 30:10732748231153775.
-
The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth. Eur J Nucl Med Mol Imaging. 2022 Oct; 49(12):4014-4024.